- Home
- PRAA vs EVMN Comparison
PRAA vs EVMN Comparison
Compare PRAA & EVMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PRAA | EVMN |
|---|---|---|
| Founded | 1996 | 2020 |
| Country | United States | United States |
| Employees | 170 | 48 |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 639.1M | 717.5M |
| IPO Year | 2002 | N/A |
Fundamental Metrics
Financial Performance| Metric | PRAA | EVMN |
|---|---|---|
| Price | $15.53 | $20.22 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 3 | 10 |
| Target Price | $24.50 | ★ $43.88 |
| AVG Volume (30 Days) | ★ 526.5K | 396.1K |
| Earning Date | 05-07-2026 | 06-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.73 | N/A |
| Revenue | ★ $1,201,837,000.00 | N/A |
| Revenue This Year | $2.01 | N/A |
| Revenue Next Year | $2.53 | N/A |
| P/E Ratio | $21.26 | ★ N/A |
| Revenue Growth | ★ 7.83 | N/A |
| 52 Week Low | $10.25 | $13.89 |
| 52 Week High | $22.55 | $33.20 |
Technical Indicators
Market Signals| Indicator | PRAA | EVMN |
|---|---|---|
| Relative Strength Index (RSI) | 46.94 | 40.05 |
| Support Level | $13.77 | $16.16 |
| Resistance Level | $15.76 | $21.21 |
| Average True Range (ATR) | 0.76 | 1.34 |
| MACD | 0.25 | -0.04 |
| Stochastic Oscillator | 78.80 | 21.98 |
Price Performance
Historical ComparisonAbout PRAA PRA Group Inc.
PRA Group Inc is a leader in acquiring and collecting nonperforming loans. The company returns capital to banks and other creditors to help expand financial services for consumers in the Americas, Europe, and Australia. It is also engaged in providing fee-based services on class action claims recoveries in the United States. The company's portfolio segments include; Core, which is engaged in purchasing and collecting nonperforming loans, which the originators have not chosen not to pursue, and the Insolvency segment which is engaged in purchasing and collecting nonperforming loans where the customer is involved in a bankruptcy proceeding.
About EVMN Evommune Inc.
Evommune Inc is a clinical-stage biotechnology company focused on creating new therapies aimed at key factors driving chronic inflammatory diseases. The initial clinical programs of the company target chronic spontaneous urticaria (CSU), atopic dermatitis (AD), and ulcerative colitis (UC). The pipeline products of the company include EVO756 and EVO301.